Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT.

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology:

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.

Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).

For more information, please visit www.verastem.com.

Verastem Oncology: Investors: John Doyle Vice President, Investor Relations & Finance +1 781-469-1546 jdoyle@verastem.com Joseph Rayne Argot Partners +1 212 600 1902 joseph@argotpartners.com Media: Lisa Buffington Corporate Communications +1 781-292-4205 lbuffington@verastem.com

Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Verastem Charts.
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Verastem Charts.